| Literature DB >> 33924645 |
Jan Mieszkowski1,2, Andżelika Borkowska3, Błażej Stankiewicz4, Andrzej Kochanowicz1, Bartłomiej Niespodziński5, Marcin Surmiak6, Tomasz Waldziński7, Rafał Rola8,9, Miroslav Petr2, Jędrzej Antosiewicz3.
Abstract
Purpose: A growing number of studies indicate the importance of vitamin D supplementation for sports performance. However, the effects of a single high-dose vitamin D supplementation on ultramarathon-induced inflammation have not been investigated. We here analyzed the effect of a single high-dose vitamin D supplementation on the inflammatory marker levels in ultramarathon runners after an ultramarathon run (maximal run 240 km).Entities:
Keywords: IL-6; inflammation; resistin; skeletal muscle damage; ultramarathon; vitamin D
Year: 2021 PMID: 33924645 PMCID: PMC8069287 DOI: 10.3390/nu13041280
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Participants’ characteristics (n = 35).
| Variable |
Supplemented Group
|
Control Group
|
| Effect Size (η2) |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| Age (years) | 42.40 ± 7.59 | 39.48 ± 6.89 | 0.21 | 0.04 |
| Body height (cm) | 175.20 ± 4.34 * | 179.67 ± 4.64 | 0.01 | 0.17 |
| Body mass | 72.51 ± 6.71 | 76.19 ± 5.25 | 0.07 | 0.08 |
| Body mass index (kg/m 2 ) | 23.24 ± 2.78 | 24.45 ± 1.19 | 0.11 | 0.06 |
| Fat mass (%) | 12.13 ± 3.89 | 12.85 ± 4.42 | 0.36 | 0.03 |
Note: *, significant difference vs. control group at p < 0.05.
Summary of training loads during typical one week of the two periods of training (N = 35).
| Number of Training Units Per Week | CR 1 | CR 2 | CROSS 1 | CROSS 2 | Speed | ||
|---|---|---|---|---|---|---|---|
| General preparation period | Mean | 5.00 | 60.94 | 11.58 | 7.58 | 3.91 | 0.88 |
| SD | 0.83 | 16.29 | 4.21 | 2.78 | 2.88 | 0.60 | |
| Pre-start preparation period | Mean | 5.70 | 67.39 | 13.52 | 14.38 | 5.7 | 1.57 |
| SD | 0.85 | 11.96 | 2.60 | 4.35 | 2.65 | 0.59 |
Note: CR 1–70–80% HR max—continuous running in the first intensity range (70–80% HRmax); CR 2–80–90% HR max—continuous running in the second intensity range (80–90% HRmax); CROSS 1—up-downhill running in different tempo (75–85% HR max); CROSS 2–up-downhill running in different tempo (85–95% HR max); Speed–100–200 meters distance running with high intensity.
Characteristics of the maximum oxygen uptake capacity (VO2 max) in ultramarathon runners basing on the Cooper test (Cooper, 1968).
| Variable | Supplemented Group | Control Group | P | Effect Size (η2) |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| VO2max | 53.73 ± 6.04 | 54.40 ± 5.68 | 0.74 | <0.01 |
| Distance (km) | 2.908 ± 0.263 | 2.939 ± 0.254 | 0.75 | <0.01 |
Note: VO2max—maximal oxygen uptake.
Ultramarathon runners performance at particular distances.
| Distance | Supplemented Group | Control Group |
| Effect Size (η2) |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| 10 km | 01:18:49 ± 00:09:28 | 01:19:28 ± 00:10:32 | 0.74 | <0.01 |
| 32 km | 05:02:36 ± 01:06:45 | 04:44:09 ± 00:59:51 | 0.32 | 0.03 |
| 64 km | 10:15:03 ± 01:30:26 | 09:47:07 ± 00:59:51 | 0.27 | 0.04 |
| 100 km | 15:57:07 ± 01:52:45 | 15:45:43 ± 01:42:34 | 0.78 | <0.01 |
| 130 km | 21:07:20 ± 02:12:27 | 19:01:51 ± 02:17:26 | 0.12 | 0.06 |
| 170 km | 29:40:07 ± 02:55:52 | 27:57:05 ± 02:23:56 | 0.16 | 0.05 |
| 215 km | 39:47:07 ± 04:01:08 | 37:35:43 ± 05:00:51 | 0.23 | 0.04 |
| 240 km | 44:46:33 ± 04:59:23 | 42:01:35 ± 05:40:04 | 0.25 | 0.04 |
Two-way ANOVA (2 groups × 3 repeated measurements) of changes in the serum vitamin D levels induced by the ultramarathon.
| Variable | Group | 24 H Before | Immediately after | 24 H after |
|---|---|---|---|---|
| 25(OH)D | Supplemented | 27.50 ± 7.01 | 58.13 ± 18.89 †# | 67.93 ± 25.67 † |
Note: Post-hoc analysis: †, significant difference vs. 24 h before the run; #, significant difference vs. group C immediately after the run. The significance level was set at p < 0.01.
Figure 1Ultramarathon track characteristics (Lower Silesian Mountain Run Festival 2018, Lądek Zdrój) (Mountain Marathons Foundation).
Figure 2Changes in biochemical marker levels after the ultramarathon in runners who receiveda single high dose of vitamin D (group S, green) and runners who received the placebo (group C, red). Sampling I, 24 h before the run; II, immediately after the run; and III, 24 h after the run. Abbreviations: FSTL-1, follistatin-like 1; IL, interleukin; LIF, leukemia inhibitory factor; OSM, oncostatin M; and TIMP-1, tissue inhibitor of metalloproteinase 1. †, Significant difference vs. 24 h before the run; #, significant difference vs. group C immediately after the run. The significance level was set at p < 0.01.
Two-way ANOVA (2 groups × 3 repeated measures) of changes in the biochemical marker levels induced by the ultramarathon.
| Variable | Effect | F | Df | P | Effect Size (η2) | Post-Hoc Outcome |
|---|---|---|---|---|---|---|
| FSTL-1 | GR | 3.26 | 1, 33 | 0.08 | 0.09 | I, III < II |
| IL-6 | GR | 5.03 | 1, 33 | 0.03 * | 0.19 | S < C |
| IL-10 | GR | 6.25 | 1, 33 | 0.02 * | 0.08 | S < C |
| IL-15 | GR | 2.17 | 1, 33 | 0.14 | 0.06 | I > III |
| Leptin | GR | 3.00 | 1, 33 | 0.09 | 0.08 | I > II |
| LIF | GR | 2.11 | 1, 33 | 0.15 | 0.06 | |
| OSM | GR | 0.11 | 1, 33 | 0.73 | 0.01 | I > II |
| Resistin | GR | 1.20 | 1, 33 | 0.27 | 0.03 | I, III < II |
| TIMP-1 | GR | 0.07 | 1, 33 | 0.78 | 0.01 | I, III > II |
Note: Markers: FSTL-1, follistatin-like 1; IL, interleukin; LIF, leukemia inhibitory factor; OSM, oncostatin M; TIMP-1, tissue inhibitor of metalloproteinase 1. Study design: GR, group; S, runners who received a single high dose of vitamin D; C, runners who received the placebo (control group); UM, ultramarathon; I, 24 h before the run; II, immediately after the run; and III, 24 h after the run. Significant difference detected at * p ≤ 0.05 or ** p ≤ 0.01.
Analysis of Pearson’s correlation (r) of changes in the serum vitamin D levels with ultramarathon-induced changes in the inflammatory marker levels.
| Variable | Change |
Supplemented Group
|
Control Group
| ||
|---|---|---|---|---|---|
| Δ I–II | Δ I–III | Δ I–II | Δ I–III | ||
| FSTL-1 | Δ I–II | 0.02 | 0.03 | 0.18 | 0.09 |
| Δ I–III | 0.31 | 0.24 | 0.19 | 0.12 | |
| IL-6 | Δ I–II | −0.37 * | −0.34 | −0.33 | −0.26 |
| Δ I–III | 0.03 | −0.01 | −0.12 | −0.12 | |
| IL-10 | Δ I–II | −0.26 | −0.19 | −0.14 | −0.11 |
| Δ I–III | 0.14 | 0.13 | 0.06 | −0.08 | |
| IL-15 | Δ I–II | −0.27 | −0.33 | −0.40 | −0.50 * |
| Δ I–III | −0.41 * | −0.45 * | −0.13 | −0.28 | |
| Leptin | Δ I–II | 0.10 | 0.20 | 0.50 * | 0.58 * |
| Δ I–III | −0.11 | −0.15 | −0.27 | −0.31 | |
| LIF | Δ I–II | 0.14 | 0.20 | 0.37 | 0.47 |
| Δ I–III | −0.19 | −0.18 | −0.06 | −0.13 | |
| Resistin | Δ I–II | −0.12 | −0.08 | 0.14 | 0.08 |
| Δ I–III | 0.17 | 0.21 | 0.26 | 0.33 | |
| OSM | Δ I–II | 0.03 | −0.14 | −0.22 | −0.43 |
| Δ I–III | 0.07 | 0.03 | 0.40 | 0.29 | |
| TIMP-1 |
Δ I–II
|
0.18
|
0.12
|
−0.07
|
−0.09
|
Note: Markers: FSTL-1, follistatin-like 1; IL, interleukin; LIF, leukemia inhibitory factor; OSM, oncostatin M; TIMP-1, tissue inhibitor of metalloproteinase 1. Study design: Δ I–II, difference between the values before and immediately after the ultramarathon; Δ I–III, difference between the values before and 24 h after the ultramarathon. Significant difference detected at * p ≤ 0.05.